Skip to main content
. 2011 Sep 2;50(11):2093–2099. doi: 10.1093/rheumatology/ker295

Fig. 3.

Fig. 3

Kaplan–Meier drug survival estimates for all biologic users. Number at risk in each group is shown at the bottom. TCZ: tocilizumab; TNFi: TNF inhibitors.